Table 2.

Clinical data of the patients used in the discovery and validation phases of the study. The patient cohorts were adjusted for age to be further sub-grouped in a discovery and a validation set.

Type of cancer	Group	Discovery set	Mean age (range)	Validation set	Mean age (range)	Sample size (%)
Prostate cancer	Case	N = 138	68 (41–87)	N = 68	68 (45–86)	10%
	Control	N = 130	66 (51–87)	N = 49	66 (51–83)	9%
Pancreatic cancer	Case	N = 61	65 (35–88)	N = 27	63 (33–90)	4%
	Control	N = 62	52 (27–77)	N = 30	52 (25–73)	4%
Renal cell carcinoma	Case	N = 46	62 (41–81)	N = 24	61 (33–79)	3%
	Control	N = 80	58 (23–84)	N = 25	59(23–84)	5%
Cholangio-carcinoma	Case	N = 82	56 (22–81)	N = 36	58 (30–86)	6%
	Control	N = 83	49 (20–83)	N = 39	50 (22–85)	6%
Bladder cancer	Case	N = 349	67 (28–95)	N = 138	69 (27–87)	24%
	Control	N = 23	60 (43–88)	N = 23	65 (33–93)	3%
Normal controls	Control	N = 167	60 (19–86)	N = 89	60 (22–86)	12%
	Individual with smoking history	N = 51	43(19–72)	N = 24	46(20–72)	4%
Inflammation controls	Control	N = 136	46(16–88)	N = 63	47(19–78)	10%
Total	Case	N = 676		N = 293		47%
	Control	N = 744		N = 342		53%
Additional cancer types
Acute myeloid leukemia				N = 27
Other tumor types				N = 13
Independent specificity analysis
Inflammatory conditions		N = 92		36 (19–63)